regardless of promising clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial opposition from managed care entities. Such companies are typically building limitations to reimbursement, such as steep price requirements and approval processes that hinder user availabil